79421-45-7

Basic information

• Product Name: 4-Hydroxy-1-(4-nitrophenyl)piperidine
• Synonyms: 4-Hydroxy-1-(4-nitrophenyl)piperidine;1-(4-Nitrophenyl)piperidin-4-ol, 4-(4-Hydroxypiperidin-1-yl)nitrobenzene;1-(4-Nitrophenyl)piperidin-4-ol
• CAS NO: 79421-45-7
• Molecular Formula: C₁₁H₁₄N₂O₃
• Molecular Weight: 222.25
• Mol File: 79421-45-7.mol
• Article Data: 19

Chemical Properties

• Melting Point: 114-116 °C(Solv: isopropanol (67-63-0))
• Boiling Point: 421.5°C at 760 mmHg
• Flash Point: 208.7°C
• Appearance: /
• Density: 1.303g/cm³
• Vapor Pressure: 7.42E-08mmHg at 25°C
• Refractive Index: 1.611
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.69±0.20(Predicted)
• CAS DataBase Reference: 4-Hydroxy-1-(4-nitrophenyl)piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Hydroxy-1-(4-nitrophenyl)piperidine(79421-45-7)
• EPA Substance Registry System: 4-Hydroxy-1-(4-nitrophenyl)piperidine(79421-45-7)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 79421-45-7(Hazardous Substances Data)

Usage

General Description

4-Hydroxy-1-(4-nitrophenyl)piperidine is a chemical compound that belongs to the class of piperidine derivatives. It is a white to yellow solid with a molecular formula of C11H14N2O3. 4-Hydroxy-1-(4-nitrophenyl)piperidine has a 4-nitrophenyl substituent attached to the piperidine ring, and a hydroxyl group at the C-4 position. It is used in the synthesis of various pharmaceuticals and agrochemicals. The compound has potential biological activities, and its derivatives have been studied for their potential as antipsychotic and anti-inflammatory agents. Studies have also shown that it exhibits antimicrobial and antifungal properties, making it a valuable compound in drug research and development.

InChI:InChI=1/C11H14N2O3/c14-11-5-7-12(8-6-11)9-1-3-10(4-2-9)13(15)16/h1-4,11,14H,5-8H2

Upstream product

• 5382-16-1 4-HYDROXYPIPERIDINE 
• 350-46-9 4-Fluoronitrobenzene 
• 6574-15-8 1-(4-nitrophenyl)piperidine 
• 100-00-5 4-chlorobenzonitrile 
• 23499-01-6 1-(4-nitrophenyl)piperidin-4-one 

Downstream Products

• 23499-01-6 1-(4-nitrophenyl)piperidin-4-one 
• 142752-12-3 4-(4-hydroxypiperidin-1-yl)aniline 
• 1244967-96-1 N-(4-(4-hydroxypiperidin-1-yl)-phenyl)-4-((1-methylpyrrol-2-yl)-carbonyl)-1-piperazinecarboxamide 
• 1415794-29-4 2-(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yloxy)ethanol 
• 1415794-27-2 tert-butyl 2-(1-(4-bromophenyl)piperidin-4-yloxy)acetate 
• 1415794-28-3 2-(1-(4-bromophenyl)piperidin-4-yloxy)ethanol 
• 211247-60-8 N,N-dimethyl-1-(4-nitrophenyl)piperidin-4-amine 
• 211247-62-0 [1-(4-Amino-phenyl)-piperidin-4-yl]-dimethyl-amine 

Relevant articles and documents

COMPOUNDS FOR TARGETED DEGRADATION OF BRD9

BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

Indazole formamide compound as well as preparation method and application thereof

The invention belongs to the field of chemical medicines, and particularly relates to an indazole formamide compound as well as a preparation method and application thereof. The invention provides anindazole carboxamide compound or a pharmaceutically acce

Design, synthesis and biological evaluation of novel 7-amino-[1,2,4]triazolo[4,3-f]pteridinone, and 7-aminotetrazolo[1,5-f]pteridinone derivative as potent antitumor agents

To develop novel therapeutic agents with anticancer activities, two series of novel 7-amino-[1,2,4]triazolo[4,3-f]pteridinone, and 7-aminotetrazolo[1,5-f]pteridinone derivatives were designed and synthesized. All compounds were tested for anti-proliferative activities against five cancer cell lines. The structure-activity relationships (SARs) studies were conducted through the variation in two regions, the moiety of A ring and the terminal aniline B on pteridinone core. 1-Methyl-1,2,4-triazole derivative L7 with 2,6-dimethylpiperazine showed the most potent antiproliferative activity against A549, PC-3, HCT116, MCF-7 and MDA-MB-231 cell lines with IC50 values of 0.16 μM, 0.30 μM, 0.51 μM, 0.30 μM, and 0.70 μM, respectively. Combined with the results of the molecular docking and enzymatic studies, the PLK1 was very likely to be one of the drug targets of compound L7. Furthermore, to clarify the anticancer mechanism of compound L7, further explorations in the bioactivity were conducted. The results showed that compound L7 obviously inhibited proliferation of A549 cell lines, induced a great decrease in mitochondrial membrane potential leading to apoptosis of cancer cells, suppressed the migration of tumor cells, and arrested G1 phase of A549 cells.